Cyclooxygenase 2 (COX-2) inhibition increases the inflammatory response in the brain during systemic immune stimuli

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Non-steroidal anti-inflammatory drugs (NSAIDs) targeting cyclooxygenase (COX) pathways are used for inflammatory conditions, including neurodegenerative disorders.
• Non-selective COX inhibition can paradoxically promote inflammation by altering glucocorticoid levels, which are crucial for innate immune response regulation.

Purpose of the Study:

• To investigate the effects of non-selective (ketorolac, indomethacin) and selective COX-1 (SC-560) or COX-2 (NS-398) inhibitors on the innate immune response in a lipopolysaccharide (LPS) mouse model.
• To elucidate the role of COX pathways in modulating LPS-induced neuroinflammation and gene expression.

Main Methods:

• Mice were challenged with lipopolysaccharide (LPS) to induce systemic inflammation.
• The expression of inflammatory genes in brain tissues was analyzed following treatment with various NSAIDs (ketorolac, indomethacin, SC-560, NS-398).
• Changes in gene expression were assessed at 3 hours post-LPS challenge.

Main Results:

• LPS challenge induced significant inflammatory gene expression in brain vascular-associated cells and microglia.
• Ketorolac, indomethacin, and the COX-2 inhibitor NS-398 significantly enhanced LPS-induced inflammatory gene expression.
• The COX-1 inhibitor SC-560 did not alter gene expression in LPS-treated animals.
• COX-2-derived prostaglandin E2 (PGE2) is implicated in the rise of glucocorticoids during immune stimuli.

Conclusions:

• Inhibition of the COX pathway, particularly COX-2, can exacerbate early innate immune reactions during systemic inflammation.
• NSAID use in inflammatory and neurodegenerative diseases requires careful consideration due to potential pro-inflammatory effects mediated by COX inhibition.
• Targeting specific COX pathways may be crucial for managing inflammation without compromising immune regulation.